Quarter Comparison
Revenue
Operating Income
Gross Margin
Net Margin
Free Cash Flow
Income Statement
Cash Flow Statement
Balance Sheet
Operating metrics disclosed this quarter
Read from the filing itself — XBRL does not carry these, so no standard financial dataset has them.
Bayer Collaboration Profit Share Rate
34.0%
Bayer records net product sales of EYLEA 8 mg and EYLEA outside the United States, and we and Bayer share profits on such sales. Regeneron's share of profits in connection with commercialization of EYLEA 8 mg and EYLEA outside the United States is summarized below: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2026 2025 2026 2025 EYLEA 8 mg and EYLEA net product sales outside the United States $ 666.5 $ 977.7 $ 1,395.2 $ 1,835.5 Regeneron's share of collaboration profit from sales outside the United States $ 242.4 $ 399.9 $ 497.8 $ 733.5 Reimbursement of development expenses incurred by Bayer in accordance with Regeneron's payment obligation(a) (15.1) (16.5) (30.5) (32.8) Regeneron's share of profits $ 227.3 $ 383.4 $ 467.3 $ 700.7 Regeneron's share of profits as a percentage of EYLEA 8 mg and EYLEA net product sales outside the United States 34% 39% 33% 38% (a) See "Collaboration, License, and Other Agreements - Bayer" above for additional details on our contingent reimbursement obligation
Sanofi Collaboration Profit Share Rate
33.0%
Global net product sales of Dupixent and Kevzara are recorded by Sanofi, and we and Sanofi share profits on such sales. Regeneron's share of profits in connection with the commercialization of Dupixent and Kevzara is summarized below: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2026 2025 2026 2025 Dupixent and Kevzara net product sales $ 6,204.1 $ 4,496.8 $ 11,229.0 $ 8,278.8 Regeneron's share of collaboration profits in connection with commercialization of antibodies $ 2,285.6 $ 1,496.7 $ 4,013.4 $ 2,676.9 Reimbursement of development expenses incurred by Sanofi in accordance with Regeneron's payment obligation(a) (253.0) (214.6) (530.0) (376.7) Regeneron's share of profits $ 2,032.6 $ 1,282.1 $ 3,483.4 $ 2,300.2 Regeneron's share of profits as a percentage of Dupixent and Kevzara net product sales 33% 29% 31% 28% (a) The Sanofi development balance, which represented our obligation to reimburse Sanofi for development expenses that were previously funded by Sanofi, was fully repaid as of June 30, 2026 and will no longer reduce our share of profits beginning in the third quarter of 2026
Gross Margin on Net Product Sales
Earnings Release
EX-99.1 2 exhibit991q22026.htm EXHIBIT 99.1 Document Exhibit 99.1 Press Release Regeneron Reports Second Quarter 2026 Financial and Operating Results • Second quarter 2026 revenues increased 17% to $4.3 billion versus second quarter 2025 • Dupixent ® global net sales (recorded by Sanofi) increased 3
EX-99.1 2 exhibit991q22026.htm EXHIBIT 99.1 Document Exhibit 99.1 Press Release Regeneron Reports Second Quarter 2026 Financial and Operating Results • Second quarter 2026 revenues increased 17% to $4.3 billion versus second quarter 2025 • Dupixent ® global net sales (recorded by Sanofi) increased 38% to a new all-time high of $6.0 billion • EYLEA HD ® U.S. net sales increased 52% to a new all-time high of $596 million • Libtayo ® global net sales increased 30% to a new all-time high of $489 million • GAAP EPS of $12.23, including $1.02 negative impact from IPR&D; non-GAAP EPS (a) of $14.29, including $0.99 negative impact from IPR&D • Sanofi Development Balance fully repaid as of end of second quarter 2026 • Cemdisiran regulatory submissions accepted for review by FDA and EMA for treatment of generalized myasthenia gravis (gMG) Tarrytown, New York (July 30, 2026) -- Regeneron Pharmaceut...
Source
Exhibit EX-99.1
0000872589-26-000023
Filed July 30, 2026 at 10:48 AM UTC. The figures above are from the audited statements, not from this release.